Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL

Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure–response relationships of obinutuzumab still n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CPT Pharmacometrics Syst Pharmacol
Hlavní autoři: Gibiansky, E, Gibiansky, L, Carlile, D J, Jamois, C, Buchheit, V, Frey, N
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4474170/
https://ncbi.nlm.nih.gov/pubmed/25353187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2014.42
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky